Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?